Domainex Ltd The company was established in 2001 and operates from sites in London and Cambridge UK. We are a privately owned company currently based on the Cambridge Science Park but due to move to the Chesterford Research Park in May 2016 into a facility that will increase our capacity from 8000 sq ft to 20000 sq ft. We have a strong track record of success in delivering pre-clinical development candidates and can work with our sponsors from the early hit finding stages of drug discovery through to integrated lead optimization. We operate a FTE-based approach to the work we undertake with results/IP out of the services we provide residing with our clients.    The key benefits of the services that Domainex Ltd offers are summarised as follows:   Combinatorial Domain Hunting – a rapid and proprietary technology to identify soluble protein domains by screening up to 100k constructs per protein in parallel   Protein expression – equipped to generate and fully characterise proteins using both E. coli and baculovirus-infected insect cell expression systems   Structural biology services – access the Domainex fragment library of 1K compounds to undertake fragment-based screening using NMR; undertake X-ray co-crystallisation studies with our CSO Professor Laurence Pearl.   LeadBuilder – a rapid and cost-effective approach to undertaking virtual screening on a virtual library of 1.4 million compounds that have been carefully selected by our medicinal chemists to have the correct lead- and drug-like properties   Computational chemistry services are provided covering pharmacophore and ligand-based approaches as well as generation of virtual libraries against targets of interest.   Bioassay Builder platform – Domainex has the capability to develop biochemical assays across a variety of target classes, e.g. protein:protein interactions, epigenetic targets and kinase assays. Our bioassay team provides just in time support for medicinal chemistry projects.   Phenotypic assay portfolio – Domainex has an established panel of cell-based assays covering cell status (viability, toxicity and stage of cell cycle) and measurement of a variety of cytokines, e.g. IL-1, IL-8, RANTES and TNFalpha. Cellular assay support is provided to our medicinal chemists to further characterise compounds being synthesised.   Hit-to-Lead medicinal chemistry services – starting with hits generated by Domainex or provided by the client, Domainex would seek to work on several series in parallel to generate at least one lead compound series with the desired properties over a defined period of 6-12 months.   Lead optimization chemistry – starting with leads either generated by Domainex or provided by the client, progressing them to pre-clinical candidates typically over a 12-18 month timeframe. Projects involve the deployment of dedicated, experienced teams of chemists with disease area expertise.   Provision of integrated medicinal chemistry projects encompassing synthetic chemistry, in vitro ADME, In vivo DMPK (via a preferred partner), biological assays, computational and analytical chemistry, working towards defined criteria for leads and pre-clinical compounds. Domainex provides the multi-disciplinary expertise and arrangements can be fee-for-service or a combination of FTE + success milestones.